What is the dose of labetalol (Normodyne)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Labetalol should be administered at an initial dose of 10-20 mg IV over 1-2 minutes for the management of elevated blood pressure in acute ischemic stroke, with the option to repeat or double the dose every 10 minutes as needed, up to a maximum dose of 300 mg, as recommended by the most recent guidelines 1. The management of blood pressure in acute ischemic stroke is a complex issue, and the use of labetalol is one of the recommended approaches. According to the guidelines, labetalol can be used to lower blood pressure in patients with acute ischemic stroke, with the goal of reducing the risk of further vascular damage and preventing early recurrent stroke. The guidelines recommend an initial dose of 10-20 mg IV over 1-2 minutes, with the option to repeat or double the dose every 10 minutes as needed, up to a maximum dose of 300 mg. Some key points to consider when using labetalol in this setting include:

  • Monitoring blood pressure closely to avoid over-treatment and potential neurological worsening
  • Adjusting the dose based on the patient's response to treatment
  • Considering alternative treatments, such as nicardipine or sodium nitroprusside, if labetalol is not effective or is contraindicated
  • Being aware of the potential side effects of labetalol, including hypotension, bradycardia, and bronchospasm. It's also important to note that the guidelines emphasize the importance of individualizing treatment and considering the patient's specific clinical circumstances, including the presence of other medical conditions and the potential for interactions with other medications 1.

From the FDA Drug Label

A substantial fall in blood pressure on standing should be expected in these patients. Either of two methods of administration of labetalol HCl injection may be used: a) repeated intravenous injections, b) slow continuous infusion Repeated Intravenous Injection Initially, labetalol HCl injection should be given in a dose of 20 mg labetalol HCl (which corresponds to 0. 25 mg/kg for an 80 kg patient) by slow intravenous injection over a 2-minute period. Additional injections of 40 mg or 80 mg can be given at 10-minute intervals until a desired supine blood pressure is achieved or a total of 300 mg labetalol HCl has been injected The effective intravenous dose is usually in the range of 50 to 200 mg A total dose of up to 300 mg may be required in some patients.

The dose of labetalol is 20 mg initially, with additional injections of 40 mg or 80 mg at 10-minute intervals, up to a total of 300 mg. The effective intravenous dose is usually in the range of 50 to 200 mg 2.

From the Research

Labetalol Dosage

  • The daily dose of labetalol used in a study published in the British journal of clinical pharmacology 3 was 600-1800 mg.
  • This study evaluated the anti-hypertensive effect of labetalol given twice or three times daily in ambulant subjects with essential hypertension.
  • The reduction in 24 h systolic and diastolic blood pressures was about 20% with labetalol treatment, regardless of whether it was given twice or three times daily.

Comparison with Other Studies

  • Other studies do not provide information on the dosage of labetalol, but rather discuss the use of other antihypertensive agents such as calcium channel blockers 4, 5 and combinations of different antihypertensive drugs 6.
  • A study on switching between β-blockers provides guidance on how to switch to a different β-blocker, but does not specifically address labetalol dosage 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Calcium channel blockers and hypertension.

Journal of cardiovascular pharmacology and therapeutics, 2015

Research

Calcium channel blockers.

Journal of clinical hypertension (Greenwich, Conn.), 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.